Solupore® RT

Solupore® Research Tool (RT) is our product offering for the application of non-viral delivery into your iPSC workflow. Solupore RT has been utilised to efficiently deliver RNA into blood cells for cell reprogramming, uniquely supporting the generation of induced pluripotent stem cells (iPSCs). In addition, we have demonstrated gene editing of iPSC and the differentiation of those iPSC to other cell types. See our collaboration with Thermo Fisher here which demonstrates the entire process workflow on generating iPSC from blood cells.

Solupore’s gentle delivery preserves cell viability and phenotype, minimising cellular perturbation during the transfection process. By eliminating the need for electroporation or viral vectors, Solupore streamlines the iPSC manufacturing workflow, reduces costs, and offers a novel delivery technology for cell line developers andregenerative medicine applications.
‍
Product Features:

Reproducible Cell Engineering System
Enabling efficient delivery of RNA into blood cells for cell reprogramming
Solupore’ gentle delivery preserves cell viability and phenotype, minimising cellular perturbation
Easy to use and small footprint

Solupore® SUS

Solupore® single use system (SUS) is our product offering for single-unit transfection at scale. Solupore SUS enables the delivery of a variety of cargo (mRNA, RNPs, DNA, plasmids) to a broad range of cell types
(T cells, NK Cells, stem cells and more). Check out our most recent publication demonstrating that Solupore-manufactured cells are more therapeutically effective in vivo.

Product Features:‍

Scalable Transfection From 3M to > 1Bn cells
Demonstrates superior metabolic activity, cell avidity and potent cytotoxicity
Easy to use, closed, automated process
GMP aligned, DMF’s filed with FDA
No buffer exchange required

Solupore® Integrated

Solupore® Integrated, currently in development at Avectas, is designed to deliver closed, end-to-end automation for CAR-T cell manufacturing, from activation through to harvest, including non-viral transfection using Avectas’ established Solupore® platform and consumables.

The system features a modular, grid-based architecture comprising an array of cell culture consumables optimised for the expansion phase. These are arranged in a high-density configuration to support simultaneous processing of multiple patient batches, enabling efficient scale-out without increasing facility footprint.

Each unit within the grid is individually monitored and controlled, providing precise regulation of key parameters such as temperature, gas exchange, and media perfusion. Solupore Integrated is engineered for seamless integration intoGMP-compliant, automated manufacturing workflows, offering scalable, reproducible production of cell therapies.See our recentISCT poster showcasing how Solupore Integrated supports CAR-T cell manufacturing.

‍Avectas Vision is Empowering Scalable and Affordable Cell Therapy. ‍

Disrupting the “One Instrument to One Consumable” Industry Standard

Market Drivers

Patient access is limited by manufacturing challenges
Low-complexity, highly-scalable manufacturing solutions required
Optimise utilisation of CGT manufacturing equipment

Early Process DevelopmentOne Instrument = One Dose

SoluporeScaled-Out Manufacturing One Instrument = Multiple Doses

End-to-end CAR-T manufacturing within one Consumable.
One instrument operating multiple Consumables to deliver multiple doses

Our technology Solupore®

Current non-viral gene delivery technologies for cell therapy can negatively impact cell quality. This impact on cell health results in reduced proliferative capacity and cell function following the delivery of cargo, particularly in complex editing workflows. By enhancing cell quality, Solupore has the potential to improve in vitro and in vivo cell function, enabling the manufacture of next-generation gene-modified cell therapies.
‍

Integration

Automated reproducible transfection: A closed and robust non-viral delivery technology that enables complex editing workflows in cell therapy manufacturing.
Versatile delivery of cargo: Transfection of a broad range of cargo and gene-editing tools, including mRNA, CRISPR/Cas9, and plasmids to T cells and other blood cells.
Full GMP support by 1H 2025: GMP instrument and reagent supported by appropriate regulatory filings.

Commercialization

Partner access to Solupore technology under a range of agreements addressing applications in autologous cell therapy and non-viral stem cell reprogramming and editing.

Solupore® Benefits

Solupore technology has the potential to enhance patient access to autologous T cell therapies through healthier and more functional engineered cells. In IPS non-viral cell reprogramming of blood cells, Solupore technology is paving the way to reprogramming cells using RNA constructs, reducing development timelines, increasing flexibility and reducing regulatory hurdles.

Maintains optimal cell health & phenotype

Enhanced cell function after payload delivery

Ability to apply payload delivery for a wide range of applications

Capable of Integrating several manufacturing unit processes

Available as cGMP instrument by 1H 2025

How solupore® works

Solupore delivers cargo by physicochemical means, reversibly permeabilizing the cell membrane and yielding cells with superior health and a younger memory phenotype. Solupore® resolves key manufacturing limitations associated with viral and non-viral cell modification approaches.

Solupore®resolves key manufacturing limitations associated with viral and non-viral cell modification approaches

Manufacturing Challenges

Problem

Solution – Solupore®

Cell health & phenotype

Electroporation unintentionally activates and exhaust cells, negatively impacting cell viability

Younger memory phenotype and reduced apoptosis leading to improved proliferative capacity

Cell function

Poor cell function post editing negatively impacts clinical efficacy, safety, and tumor killing capability

Due to improved cell health and proliferative capacity, T cells are highly functional in vitro and in vivo

Complex gene-editing

Constraints around processing time, inflexibility and yield for sequential edits

Improved cell heath and function enable the complex editing needed for the next generation of cell therapies

Ease of adoption and use

Time consuming to scale up and cell processing requires highly skilled operators with batch-to-batch variability

Automated and closed system with minimal cell processing, flexible input parameters and ease of use

Cost of Goods

Multiple platforms and open steps

Cells processed within one closed device

Our technology ‍Solupore®